Second Genome is a venture capital funded, life sciences research company based in South San Francisco.[1] The company's focus is on the development and exploitation of a research platform which facilitates the identification and elucidation of relationships between human physiology and the human microbiota,[1][2] and it has a long term goal of becoming a drug development company.[3] The name "second genome" comes from the notion that humans have, effectively, two genomes: the native human genome, and the more diverse set of genomes carried by the human microbiota.[4]
The company's first foray into drug development was a small molecule treatment for ulcerative colitis (SGM-1019).[3][5][notes 1][notes 2] The mechanism of SGM-1019 has not been disclosed in detail.[5] Key to the company's business model has been partnerships with large established pharmaceutical companies, including Pfizer and Janssen.[1] Potential competitors to Second Genome include Kaleido Biosciences, Synlogic, Kallyope, Seres Therapeutics, OpenBiome, Rebiotix, Evelo Therapeutics,[2] and Vedanta Biosciences.[3]
Second Genome was founded in 2010 by Corey Goodman, a venture capitalist and former Pfizer executive,[3] and Todd DeSantis, the company's vice president for informatics as of 2019.[6] As of 2013, the company had entered into an ulcerative colitis research agreement with Janssen,[7] the financial arrangement and outcome of which remains to be determined. The company had a headcount of 18 employees as of 2014,[update][1] which had increased to 25 by 2016.[3] Startup financing was obtained through a Series A round which raised US$11.5 million.[1] A Series B round of funding raised US$42.6 million in 2016.[3] By 2016, the company had established a DNA sequencing service aimed at microbial samples, which provided revenue to supplement venture capital infusions.[3] As of 2019, the company had secured a two-year SBIR grant in collaboration with Oregon State University, aimed at studying microbiome metabolites from people suffering from nervous system disorders, in particular autism.[6]
^Searches in clinicaltrials.gov on 3 August 2017 did not reveal information about trials sponsored by Second Genome or using the therapeutic SGM-1019.
^Timmerman 2016 refers to indication being ulcerative colitis; Lash 2015 refers to indication being Crohn's disease.
Referencesedit
^ abcdefKoberstein, Wayne (July 2014). "Second Geome". Companies To Watch. Life Science Leader. 6 (7). Jameson Publishing: 14.
^ abJacobson, Don (19 July 2017). "Mayo Continues Venture Funding of Gut Microbiome Companies with Latest Stake". Twin Cities Business. Minnesota, United States: MSP Communications. Retrieved 4 August 2017. Second Genome's product is essentially a platform that combines genomics technologies, computational biology, and phenotypic screening which allows researchers to develop drugs....
^ abcdefghTimmerman, Luke (20 April 2016). "Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome". Forbes.
^Shukla, Triveni P. (2014). Our Genes, Our Foods, Our Choices. Bloomington, Indiana, United States: Author House. p. 89. ISBN9781496928580. OCLC 890626454. One hundred trillion bacteria in our colon and their genes, our second genome, matter to our immunity and sustainable health. --Triveni P. Shukla
^ abLash, Alex (12 January 2015). "Second Genome Has Begun First Drug Trial Based on Microbiome Secrets". Xconomy. Retrieved 4 August 2017.
^ abLundeberg, Steve (25 May 2019). "OSU part of $1.94 million grant to study connection between autism, microbiome". The World. Oregon, United States: Lee Enterprises. p. A12. Retrieved 12 February 2021 – via Newspapers.com.
^Sell, David (9 June 2013). "Large, small drug firms join for profitable results". The Philadelphia Inquirer. Vol. 185, no. 9. Interstate General Media. p. D4. Retrieved 12 February 2021 – via Newspapers.com.
External linksedit
Corporate Website: www.secondgenome.com
This corporation or company article is a stub. You can help Wikipedia by expanding it.
second, genome, venture, capital, funded, life, sciences, research, company, based, south, francisco, company, focus, development, exploitation, research, platform, which, facilitates, identification, elucidation, relationships, between, human, physiology, hum. Second Genome is a venture capital funded life sciences research company based in South San Francisco 1 The company s focus is on the development and exploitation of a research platform which facilitates the identification and elucidation of relationships between human physiology and the human microbiota 1 2 and it has a long term goal of becoming a drug development company 3 The name second genome comes from the notion that humans have effectively two genomes the native human genome and the more diverse set of genomes carried by the human microbiota 4 Second GenomeFounded2010 FounderCorey GoodmanTodd DeSantisHeadquartersSouth San Francisco United States Key peoplePeter DiLaura President CEO as of 2016 Number of employees25 2016 Websitewww wbr secondgenome wbr com The company s first foray into drug development was a small molecule treatment for ulcerative colitis SGM 1019 3 5 notes 1 notes 2 The mechanism of SGM 1019 has not been disclosed in detail 5 Key to the company s business model has been partnerships with large established pharmaceutical companies including Pfizer and Janssen 1 Potential competitors to Second Genome include Kaleido Biosciences Synlogic Kallyope Seres Therapeutics OpenBiome Rebiotix Evelo Therapeutics 2 and Vedanta Biosciences 3 Second Genome was founded in 2010 by Corey Goodman a venture capitalist and former Pfizer executive 3 and Todd DeSantis the company s vice president for informatics as of 2019 6 As of 2013 the company had entered into an ulcerative colitis research agreement with Janssen 7 the financial arrangement and outcome of which remains to be determined The company had a headcount of 18 employees as of 2014 update 1 which had increased to 25 by 2016 3 Startup financing was obtained through a Series A round which raised US 11 5 million 1 A Series B round of funding raised US 42 6 million in 2016 3 By 2016 the company had established a DNA sequencing service aimed at microbial samples which provided revenue to supplement venture capital infusions 3 As of 2019 the company had secured a two year SBIR grant in collaboration with Oregon State University aimed at studying microbiome metabolites from people suffering from nervous system disorders in particular autism 6 As of 2016 update the company s president and chief executive officer was Peter DiLaura 1 3 Notes edit Searches in clinicaltrials gov on 3 August 2017 did not reveal information about trials sponsored by Second Genome or using the therapeutic SGM 1019 Timmerman 2016 refers to indication being ulcerative colitis Lash 2015 refers to indication being Crohn s disease References edit a b c d e f Koberstein Wayne July 2014 Second Geome Companies To Watch Life Science Leader 6 7 Jameson Publishing 14 a b Jacobson Don 19 July 2017 Mayo Continues Venture Funding of Gut Microbiome Companies with Latest Stake Twin Cities Business Minnesota United States MSP Communications Retrieved 4 August 2017 Second Genome s product is essentially a platform that combines genomics technologies computational biology and phenotypic screening which allows researchers to develop drugs a b c d e f g h Timmerman Luke 20 April 2016 Pfizer Roche Embrace The Microbiome Leading 43M Bet On Second Genome Forbes Shukla Triveni P 2014 Our Genes Our Foods Our Choices Bloomington Indiana United States Author House p 89 ISBN 9781496928580 OCLC 890626454 One hundred trillion bacteria in our colon and their genes our second genome matter to our immunity and sustainable health Triveni P Shukla a b Lash Alex 12 January 2015 Second Genome Has Begun First Drug Trial Based on Microbiome Secrets Xconomy Retrieved 4 August 2017 a b Lundeberg Steve 25 May 2019 OSU part of 1 94 million grant to study connection between autism microbiome The World Oregon United States Lee Enterprises p A12 Retrieved 12 February 2021 via Newspapers com Sell David 9 June 2013 Large small drug firms join for profitable results The Philadelphia Inquirer Vol 185 no 9 Interstate General Media p D4 Retrieved 12 February 2021 via Newspapers com External links editCorporate Website www wbr secondgenome wbr com nbsp This corporation or company article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Second Genome amp oldid 1177463189, wikipedia, wiki, book, books, library,
